临床试验/NCT01218360

NCT01218360已完成不适用

Observational Study on Disease Severity, Evaluation Tools and the Long Term Impact of Each Treatment Strategy in the Daily Clinical Practice in Patients With Moderate to Severe Active Crohn's Disease (Protocol P06484)

Merck Sharp & Dohme LLC0 个研究点目标入组 71 人开始时间: 2011年11月最近更新: 2015年3月19日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Merck Sharp & Dohme LLC
入组人数: 71
主要终点: Record of treatment strategy followed

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is an observational study to determine the prevalence of moderate to severe Crohn's disease (CD) among patients with active CD and to evaluate existing therapeutic trends in a standard clinical practice.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Participants

All participants enrolled

干预措施: Physician standard-of-care (Drug)

结局指标

主要结局

Record of treatment strategy followed

时间窗: Week 0 to 2 years

Percentage of Crohn's disease participants among the study population with a Crohn's Disease Activity Index (CDAI) score of 220-450 at the enrollment to the study.

时间窗: Week 0

Change in the CDAI score during the observational period

时间窗: Week 0 to 2 years

次要结局

Number of surgeries and hospitalizations during the observational period(Week 0 to 2 years)

研究者

发起方

Merck Sharp & Dohme LLC

申办方类型

Industry

责任方

Sponsor

相似试验

Unknown

不适用

Observational Prospective Study to Identify Intestinal Microbial Profiles in Newly Diagnosed Crohn's Disease PatientsCrohn Disease

NCT06324591Meyer Children's Hospital IRCCS30

招募中

2 期

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseCrohn's Disease

NCT06548542AbbVie540

撤回

2 期

Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's DiseaseCrohns DiseaseCrohn's Disease

NCT04151225GlaxoSmithKline

招募中

3 期

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseCrohn's Disease

NCT06332534AbbVie110

进行中（未招募）

1 期

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's DiseaseCrohn's Disease

NCT03992469Icahn School of Medicine at Mount Sinai7